NaotoUenoMDMD, PhD(He/Him)

Oncology • Honolulu, HI

Breast Cancer

University of Hawaiʻi Cancer Center Director Professor of Medicine

Join to view full profile

Dr. Ueno is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ueno's full profile

Already have an account?

Office
701 Ilalo Street, Room 622
Honolulu, HI 96813
Phone+1 808-586-3013

Summary

I am a board-certified internist and medical oncologist. I specialize in taking care of patients with inflammatory breast cancer, triple negative breast cancer, metastatic breast cancer, and bone metastasis. I have a passion to provide the best care to my patients.

Education & Training

UT Graduate School of Biomedical SciencePhD, Cancer Biology, 1994 - 1999
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1993 - 1996
UPMC Medical EducationResidency, Internal Medicine, 1990 - 1993
OtherClass of 1989

Certifications & Licensure

HI State Medical License 2022 - 2026
TX State Medical License 1993 - 2024
FL State Medical License 2021 - 2023
OK State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regents’ Outstanding Teaching Award The University of Texas System, 2013

Clinical Trials

Herceptin and GM-CSF for Metastatic Breast Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 2
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer Start of enrollment: 2007 Apr 17
Recruiting
Roles: Contact, Principal Investigator
Denosumab for Breast Cancer With Bone Mets Start of enrollment: 2015 Feb 09
Terminated
Phase 2
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy Start of enrollment: 2015 Jun 11
Active, not recruiting
Phase 2
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery Start of enrollment: 2016 Aug 01
Terminated
Phase 2
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Start of enrollment: 2016 Sep 22
Completed
Phase 2
Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study Start of enrollment: 2020 Nov 03
Recruiting
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Start of enrollment: 2021 Nov 04
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Start of enrollment: 2022 Aug 15
Active, not recruiting
Roles: Contact, Principal Investigator
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body Start of enrollment: 2022 Nov 08
Terminated
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

47 citations
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer
Funda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, Senthil Damodaran, Chetna Wathoo
JCO Precision Oncology. 2018-04-25
588 citations
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
Daniel J. McGrail, Patrick G. Pilie, Naim U. Rashid, Leonie Voorwerk, Maarten Slagter
Annals of Oncology. 2021-03-15
1469 citations
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik
Nature. 2016-06-02

Journal Articles

Rates of Immune Cell Infiltration in Patients with Triple-Negative Breast Cancer by Molecular Subtype
Wendy A Woodward, Naoto T Ueno, Savitri Krishnamurthy, Bora Lim, PLoS One
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer
Michael C Stauder, Anthony Lucci, Wendy A Woodward, Bora Lim, Naoto T Ueno, ScienceDirect

Lectures

Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018
Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018
Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018
Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018
An Oncologist-Turned-Cancer-Patient’s Plea to ColleaguesMay 2018
An Oncologist-Turned-Cancer-Patient’s Plea to ColleaguesMay 2018
My Methodology: How I Treat Inflammatory Breast CancerApril 2018
5 Items Patients (And You) Should Complete to Prepare for the End of LifeJanuary 2018
Prior Systemic Treatment Increased the Incidence of Somatic Mutations in Metastatic Breast CancerJanuary 2018
Join now to see all

Press Mentions

Five Questions with Dr. Naoto Ueno, UH Cancer Center's New DirectorJanuary 30th, 2023
MD Anderson Research Highlights for December 19, 2022December 19th, 2022
Oncologist to Lead Northwell Health Cancer InstituteOctober 18th, 2022
Join now to see all